Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cutting-edge approaches to B-cell depletion in autoimmune diseases.
Robinson WH, Fiorentino D, Chung L, Moreland LW, Deodhar M, Harler MB, Saulsbery C, Kunder R. Robinson WH, et al. Among authors: kunder r. Front Immunol. 2024 Oct 9;15:1454747. doi: 10.3389/fimmu.2024.1454747. eCollection 2024. Front Immunol. 2024. PMID: 39445025 Free PMC article. Review.
A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers.
Han LW, Jamalian S, Hsu JC, Sheng XR, Yang X, Yang X, Monemi S, Hassan S, Yadav R, Tuckwell K, Kunder R, Pan L, Glickstein S. Han LW, et al. Among authors: kunder r. Rheumatol Ther. 2024 Jun;11(3):755-771. doi: 10.1007/s40744-024-00670-5. Epub 2024 Apr 25. Rheumatol Ther. 2024. PMID: 38662148 Free PMC article.
Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases.
Yadav R, Sukumaran S, Lutman J, Mitra MS, Halpern W, Sun T, Setiadi AF, Neighbors M, Sheng XR, Yip V, Shen BQ, Liu C, Han L, Ovacik AM, Wu Y, Glickstein S, Kunder R, Arron JR, Pan L, Kamath AV, Stefanich EG. Yadav R, et al. Among authors: kunder r. J Pharm Sci. 2023 Nov;112(11):2910-2920. doi: 10.1016/j.xphs.2023.07.005. Epub 2023 Jul 8. J Pharm Sci. 2023. PMID: 37429356 Free article.
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Tang F, Kunder R, Chu T, Hains A, Nguyen A, McBride JM, Zhong Y, Santagostino S, Wilson M, Trenchak A, Chen L, Ly J, Moein A, Lewin-Koh N, Raghavan V, Osaghae U, Wynne C, Owen R, Place D. Tang F, et al. Among authors: kunder r. Clin Transl Sci. 2023 Sep;16(9):1653-1666. doi: 10.1111/cts.13576. Epub 2023 Jul 23. Clin Transl Sci. 2023. PMID: 37350225 Free PMC article. Clinical Trial.
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Chen H, et al. Among authors: kunder r. Pulm Pharmacol Ther. 2022 Aug;75:102133. doi: 10.1016/j.pupt.2022.102133. Epub 2022 May 26. Pulm Pharmacol Ther. 2022. PMID: 35644305 Clinical Trial.
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R, Velyunskiy M, Dunne SF, Cho BK, Kanojia D, Begg L, Orriols AM, Fleming-Trujillo E, Vadlamani P, Vialichka A, Bolin R, Perrino JN, Roth D, Clutter MR, Zielinski-Mozny NA, Goo YA, Cristofanilli M, Mendillo ML, Vassilopoulos A, Horiuchi D. Kunder R, et al. Cell Chem Biol. 2022 Mar 17;29(3):358-372.e5. doi: 10.1016/j.chembiol.2021.08.011. Epub 2021 Sep 14. Cell Chem Biol. 2022. PMID: 34525344 Free PMC article.
24 results